Skip to main content

Recombinant Mouse IDO Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 9157-AO

Indoleamine 2,3-dioxygenase
R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
9157-AO-010

Key Product Details

Source

E. coli

Accession #

Conjugate

Unconjugated

Applications

Enzyme Activity

Product Specifications

Source

E. coli-derived mouse Indoleamine 2,3-dioxygenase/IDO protein
Ala2-Pro407, with an N-terminal Met and 6-His tag

Purity

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Met

Predicted Molecular Mass

46 kDa

SDS-PAGE

41 kDa, reducing conditions

Activity

Measured by its ability to oxidize L-tryptophan to N-formyl-kynurenine.
The specific activity is >1,000 pmol/min/μg, as measured under the described conditions.

Formulation, Preparation and Storage

9157-AO
Formulation Supplied as a 0.2 μm filtered solution in Sodium Acetate, NaCl and Glycerol.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Background: Indoleamine 2,3-dioxygenase/IDO

Indoleamine 2,3-dioxygenase (IDO) is a heme-containing intracellular dioxygenase that catalyzes the degradation of the essential amino acid L-tryptophan to N formyl kynurenine. This degradation is the first and rate-limiting step of the L-kynurenine pathway (1). IDO expression is induced in macrophages, plasmacytoid dendritic cells (pDC), and microglia by multiple inflammatory stimuli including IFN-g, TNF-a, CpG DNA, HIV-1 Tat protein, microbial infection, or GITR Ligand activation (2-9). It can be expressed by tumor cells, pDC in tumor draining lymph nodes, and MDSC in breast cancer (10-12). IDO expression is critical for the ability of these cells to induce the activation of resting Treg and the support of immune tolerance to apoptotic cell debris (7, 11, 13). These cells also suppress anti-tumor immunity (10, 12), the development of autoimmunity (13), and the replication of Chlamydia, Herpes simplex virus, and measles virus (3, 4, 14). In the absence of IDO function, activation of pDC does not induce immunosuppression but instead triggers IL-6 production and the redirecting of Treg to produce IL-17 (7). Mouse IDO shares 61% and 87% amino acid sequence identity with human and rat IDO, respectively (15).

References

  1. Munn, D.H. and A.L. Mellor (2016) Trends Immunol. 37:193.
  2. Thomas, S.R. et al. (1994) J. Biol. Chem. 269:14457.
  3. Carlin, J.M. et al. (1989) J. Interferon Res. 9:329.
  4. Adams, O. et al. (2004) Microbes Infect. 6:806.
  5. Planes, R. and E. Bahraoui (2013) PLoS One 8:e74551.
  6. O'Connor, J.C. et al. (2009) J. Neurosci. 29:4200.
  7. Baban, B. et al. (2009) J. Immunol. 183:2475.
  8. Grohmann, U. et al. (2007) Nat. Med. 13:579.
  9. Loughman, J.A. and D.A. Hunstad (2012) J. Infect. Dis. 205:1830.
  10. Holmgaard, R.B. et al. (2015) Cell Rep. 13:412.
  11. Sharma, M.D. et al. (2007) J. Clin. Invest. 117:2570.
  12. Yu, J. et al. (2013) J. Immunol. 190:3783.
  13. Ravishankar, B. et al. (2012) Proc. Natl. Acad. Sci. USA 109:3909.
  14. Obojes, K. et al. (2005) J. Virol. 79:7768.
  15. Habara-Ohkubo, A. et al. (1991) Gene 105:221.

Alternate Names

3dioxygenase, IDO, IDO1, INDO, Indoleamine 2

Entrez Gene IDs

3620 (Human); 15930 (Mouse)

Gene Symbol

IDO1

UniProt

Additional Indoleamine 2,3-dioxygenase/IDO Products

Product Documents for Recombinant Mouse IDO Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Mouse IDO Protein, CF

For research use only

Loading...
Loading...
Loading...